Ly5830966

Phase 1

Eli Lilly

Ly5830966 is one of 19 therapeutic programs targeting Primary Myelofibrosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Primary MyelofibrosisRecruiting

Primary MyelofibrosisPhase 1

Recruiting

Competition

Competitive Landscape

19 competitors in Primary Myelofibrosis

#DrugCompanyPhaseTrials

Jakafi

Incyte

Approved

3 2

Thalomid

Zometa

Farydak

2 5

Vonjo

SSobi, Inc.

Approved

—6

Pomalyst

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Trisenox

Ojjaara

GGlaxo Dba Glaxosmithkline

BESREMI

1 10

Fludara

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Primary Myelofibrosis

NCT06343805

Clinical

Trials by Indication[1]

Primary Myelofibrosis1 trial

A Phase 1, Open-Label Study of LY5830966, a Type II JAK2 Inhibitor, in Patients With Myelofibrosis Previously Treated With a Type I JAK2 Inhibitor, JAK2 Inhibitor-Naïve Myelofibrosis, or High-risk Relapsed/Refractory Polycythemia Vera

Recruiting·AAjax Therapeutics, Inc.·Phase 1·NCT06343805·256 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ly5830966. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ly5830966. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Eli Lilly

Ly5830966

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Primary Myelofibrosis1 trial

References

Drug Info

Quick Facts

Related News